Specialty focus enables UCB to repel austerity
This article was originally published in Scrip
Executive Summary
By focusing on specialty drugs for severe neurological and immunology disorders UCB CEO Roch Doliveux believes his company is positioned well to cope with payer pressures in the developed world while making major headway in key emerging markets. Indeed, in his last year at the helm, Mr Doliveux is expecting UCB to deliver double digit EBITDA and EPS growth in 2014.